Neurostimulation startup Neuros Medical, which is developing a device to block the chronic pain of amputees, has secured a new investor in RiverVest Venture Partners.
RiverVest will participate in Neuros’ next funding round, which is expected to close in a few months and is being led by existing investor Glengary. Neuros CEO Jon Snyder has said the Cleveland-area company is targeting $3.5 million for the round, which the company is labeling a series A1.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Neuros is developing a device that uses a pacemaker-sized generator and an electrode to stimulate nerves to block pain from amputations — sometimes called stump pain — without the use of drugs. In November, Neuros received regulatory approval to begin a pilot clinical trial of the device.
Snyder has said he anticipates market launch of the device sometime in 2014.
Neuros raised $1.8 million in 2009. A year later, the company received a $1.5 million grant from the U.S. Department of Defense, as the device holds promise in helping relieve pain for soldiers who have lost limbs.
St. Louis-based RiverVest has enjoyed a strong run recently with its healthcare investments. The venture firm said it exited four healthcare portfolio companies last year, with sales to the likes of industry giants Medtronic and Pfizer.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
[Photo from flickr user 1-25_sbct]
